HC Wainwright reissued their buy rating on shares of Capricor Therapeutics (NASDAQ:CAPR) in a report published on Tuesday. HC Wainwright currently has a $9.00 price target on the biotechnology company’s stock.

“Valuation and potential impediments to achieving it. We reiterate our Buy rating and $8.60 price target. Our price target is based on our clinical net present value (NPV) model, which is currently driven by the company’s lead asset, CAP-1002 in DMD patients. We believe this method is appropriate in capturing the value of the clinical stage pipeline by allowing us to flex multiple assumptions, including chance of success, peak sales estimates, and year of commercial launch.”,” the firm’s analyst wrote.

Several other equities research analysts have also recently issued reports on the stock. Maxim Group reaffirmed a buy rating and set a $4.00 price objective on shares of Capricor Therapeutics in a research report on Wednesday, November 14th. TheStreet cut shares of Capricor Therapeutics from a c- rating to a d+ rating in a research report on Monday, October 15th. Finally, Zacks Investment Research raised shares of Capricor Therapeutics from a sell rating to a hold rating in a research report on Wednesday, October 10th. Two equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company currently has a consensus rating of Buy and a consensus target price of $4.83.

CAPR stock traded down $0.05 during midday trading on Tuesday, hitting $0.80. The company’s stock had a trading volume of 20,718 shares, compared to its average volume of 165,993. Capricor Therapeutics has a 52-week low of $0.66 and a 52-week high of $2.48. The stock has a market capitalization of $27.28 million, a PE ratio of -1.82 and a beta of -2.24.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings data on Tuesday, November 13th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.01). The firm had revenue of $0.22 million for the quarter, compared to analysts’ expectations of $0.90 million. Capricor Therapeutics had a negative return on equity of 159.36% and a net margin of 24.75%. On average, sell-side analysts predict that Capricor Therapeutics will post -0.53 earnings per share for the current fiscal year.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

See Also: How Investors Use a Balance Sheet

Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.